COSMOS Pharmaceutical Third Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St · 04/15 23:12

COSMOS Pharmaceutical (TSE:3349) Third Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥246.3b (up 3.1% from 3Q 2024).
  • Net income: JP¥7.92b (up 37% from 3Q 2024).
  • Profit margin: 3.2% (up from 2.4% in 3Q 2024). The increase in margin was driven by higher revenue.
  • EPS: JP¥99.87 (up from JP¥72.80 in 3Q 2024).
We check all companies for important risks. See what we found for COSMOS Pharmaceutical in our free report.
earnings-and-revenue-growth
TSE:3349 Earnings and Revenue Growth April 15th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

COSMOS Pharmaceutical EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 31%.

Looking ahead, revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan.

Performance of the Japanese Consumer Retailing industry.

The company's shares are up 9.9% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of COSMOS Pharmaceutical's balance sheet and an in-depth analysis of the company's financial position.